Drug Profile


Alternative Names: BAY-865319; BOL-303242-X; ZK 245186

Latest Information Update: 21 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bausch & Lomb; Bayer HealthCare Pharmaceuticals
  • Class Anti-inflammatories; Corticosteroids; Skin disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic conjunctivitis; Atopic dermatitis; Dry eyes; Ocular inflammation; Ocular pain

Most Recent Events

  • 31 Aug 2013 Bausch & Lomb completes a phase III trial in Ocular pain & inflammation in USA (NCT01591161)
  • 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
  • 31 Jul 2013 Bausch & Lomb completes a phase I trial in Healthy volunteers in USA (NCT01736462)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top